On February 24, Sansure Biotech Inc(688289) released the annual performance express of 2021. In 2021, the company achieved a revenue of 4.505 billion yuan and a net profit of 2.222 billion yuan.
It is reported that the “Shengxiang program” has become the leading program of anti epidemic in many countries around the world. During the reporting period, Sansure Biotech Inc(688289) covid-19 nucleic acid detection reagent delivered 219 million people, an increase of 134.66% over the same period of the previous year. A total of 10696 instruments were shipped in the whole year, an increase of 74.71% over the same period of the previous year, which provided strong support for further driving the amount of reagents and accelerating the improvement of the market share of the whole line of products.
It is worth noting that covid-19 business gradually drives the expansion of Sansure Biotech Inc(688289) strategic production line. In the first three quarters of 2021, the company’s non covid-19 business revenue was 875 million yuan, accounting for 26.78%, an increase of 26.02% over the same period last year.
Sansure Biotech Inc(688289) said that according to the assessment indicators of the stock incentive plan, it is estimated that the business income of the strategic production line will maintain an annual growth rate of more than 30%. With the help of the advantageous resources accumulated in the early market development, it will further enhance the in-depth layout of strategic production lines such as respiratory tract, hepatitis, HPV, women and children in the international market.
Since December 2021, Sansure Biotech Inc(688289) hpv13 + 2, covid-19 and other strategic production line products have been listed successively, and the second growth curve of Sansure Biotech Inc(688289) is accelerating.
In 2021, Sansure Biotech Inc(688289) continued to increase R & D. in 2021, the company’s R & D expenditure reached 185 million yuan, a significant increase of 124% over the same period last year. According to the data, during the reporting period, the company obtained 132 new foreign product registrations.
At present, Sansure Biotech Inc(688289) has carried out continuous development and layout in the fields of covid-19 full scene scheme, accurate detection of respiratory tract, blood safety, early screening, early diagnosis and accompanying of tumor, second-generation sequencing and automatic instruments and equipment, and nearly 100 key projects are being accelerated.
In 2021, Sansure Biotech Inc(688289) increased marketing reform and channel construction. At present, the company has built a marketing team with more than 1000 people, and the team strength has been greatly enhanced. According to the relevant person in charge, the marketing team adheres to customer-oriented, market-oriented and front-line, focuses more on the development of strategic production lines, and sinks the overall solution of Shengxiang to all medical institutions in cities, districts and counties.
In the overseas market, Sansure Biotech Inc(688289) localization operation has also been substantially started. Sansure Biotech Inc(688289) accelerate the layout on the basis of “7 + 2” and formulate the “5 + 10” overseas strategy, focusing on five regions: Europe, South Asia Oceania, North Asia CIS, Middle East Africa and America, and ten countries such as France, Britain and the Philippines. Through the mode of localized operation, we will deeply cultivate key countries and regions, set up branches and subsidiaries, strengthen cooperation with international enterprises, and further expand the business scope and global influence of the company.
Sansure Biotech Inc(688289) said that on the basis of focusing on its main business, it will lay out key tracks in the field of in vitro diagnosis, further increase investment in key underlying technologies, key core modules and key raw materials, and build a perfect and comprehensive platform company.
